Tolebrutinib Nears FDA Decision, Offering New Hope for MS Patients

A potential breakthrough in multiple sclerosis (MS) treatment is on the horizon as the FDA grants priority review to tolebrutinib, a promising therapy aimed at slowing disability progression in non-relapsing secondary progressive MS (nrSPMS). Unlike conventional treatments focused on relapse management, tolebrutinib targets smoldering neuroinflammation, a persistent form of inflammation in the brain that drives disability over time. The decision, expected by September 28, 2025, could mark a turning point for patients facing the challenges of progressive MS. A parallel regulatory review is also underway in Europe, reinforcing global momentum for this innovative therapy.

Supported by phase 3 trials HERCULES, GEMINI 1, and GEMINI 2, tolebrutinib has shown potential in addressing disability accumulation beyond relapse activity, offering new hope to MS patients who have limited treatment options. According to Dr. Erik Wallström, Global Head of Neurology Development, the data underscores the urgent need for therapies that address the root causes of neurodegeneration. While the drug remains under clinical investigation, ongoing studies—like the PERSEUS trial for primary progressive MS—could further solidify its role in reshaping the MS treatment landscape.